Department of Anesthesia, Perioperative Medicine and Pain Management, Dalhousie University, Nova Scotia Health Authority and IWK Health Centre, Halifax, NS, Canada.
Can J Anaesth. 2020 Nov;67(11):1557-1575. doi: 10.1007/s12630-020-01793-3. Epub 2020 Aug 17.
The goal of the present systematic review is to determine the efficacy of the quadratus lumborum block (QLB) in providing postoperative analgesia for abdominal wall and hip surgeries when compared with placebo or other analgesic techniques.
Electronic databases (Medline, Embase, Cochrane Central, and Scopus) were searched for keywords and controlled vocabulary terms related to QLB from their inception to November 2019. The included studies compared ultrasound-guided single-injection QLB to placebo and other analgesic techniques in adult patients.
Forty-two randomized-controlled trials provided the data for this systematic review. Eight studies were assessed as high risk of bias in at least one domain. The included studies had significant heterogeneity with regard to the type of surgery, comparator groups, and outcomes measured; therefore, a limited quantitative analysis was undertaken for the comparison of QLB vs no block or placebo in patients undergoing Cesarean delivery only. For Cesarean delivery, the QLB reduced the opioid use by 24.1 (95% confidence interval, 17.3 to 30.9) mg oral morphine equivalents in the first postoperative 24 hr compared with no block or placebo with no difference in pain scores at rest. For other surgical procedures, the pain scores and opioid use were lower in the QLB group when compared with placebo or no regional anesthesia technique. When compared with other regional anesthetic techniques, the analgesic benefit of QLB was marginal.
Quadratus lumborum block provided analgesic benefits compared with placebo for use in the abdominal wall and hip surgery, with only marginal benefits compared with other regional analgesic techniques. The identified studies used different variants of QLB in many different surgery types. These findings and conclusions, therefore, should be considered preliminary.
PROSPERO (CRD42018095965); registered 6 June 2018.
本系统评价的目的是确定竖脊肌阻滞(QLB)在提供腹壁和髋关节手术后镇痛方面的疗效,与安慰剂或其他镇痛技术相比。
从建库开始到 2019 年 11 月,电子数据库(Medline、Embase、Cochrane 中央和 Scopus)使用与 QLB 相关的关键词和受控词汇进行搜索。纳入的研究比较了超声引导下单次注射 QLB 与安慰剂和其他镇痛技术在成年患者中的应用。
42 项随机对照试验为这项系统评价提供了数据。有 8 项研究在至少一个领域被评估为高偏倚风险。纳入的研究在手术类型、对照组和测量的结果方面存在显著的异质性;因此,仅对仅行剖宫产的患者中 QLB 与无阻滞或安慰剂的比较进行了有限的定量分析。对于剖宫产,与无阻滞或安慰剂相比,QLB 在术后 24 小时内减少了 24.1mg(95%置信区间,17.3 至 30.9)mg 口服吗啡等效物的阿片类药物使用,而在静息时疼痛评分方面没有差异。对于其他手术,与安慰剂或无区域麻醉技术相比,QLB 组的疼痛评分和阿片类药物使用量较低。与其他区域麻醉技术相比,QLB 的镇痛效果略有优势。
与安慰剂相比,QLB 用于腹壁和髋关节手术可提供镇痛益处,与其他区域镇痛技术相比仅具有轻微优势。已识别的研究在许多不同的手术类型中使用了不同变体的 QLB。因此,这些发现和结论应被视为初步的。
PROSPERO(CRD42018095965);2018 年 6 月 6 日注册。